Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Clemons

Showing results (241-250 of 267) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163Susan L Ellard, Mark Clemons, Karen A Gelmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of responseNan Soon Wong, Robert A Buckman, Mark Clemons, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2009
Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastasesKristin Harris, Edward Chow, Liying Zhang, et al.
Cancer Research|August 14, 2015
Perivascular M2 Macrophages Stimulate Tumor Relapse after ChemotherapyRussell Hughes, Bin-Zhi Qian, Charlotte Rowan, et al.
Journal of Evaluation in Clinical Practice|January 24, 2019
Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trialSusan J Robertson, Mohammed F K Ibrahim, Carol Stober, et al.
JCO Clinical Cancer Informatics|November 27, 2023
Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data SetsSamer El Kababji, Nicholas Mitsakakis, Xi Fang, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2020
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michael Ong, Carol Stober, et al.
Breast Cancer Research and Treatment|August 21, 2025
Patient perceptions around the use of clinico-pathologic and genomic tools in the management of early breast cancerAna-Alicia Beltran-Bless, Deanna Saunders, Lucas Clemons, et al.
Cell Metabolism|September 15, 2015
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast CancerFanny Dupuy, Sébastien Tabariès, Sylvia Andrzejewski, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 4, 2018
A prospective intervention to improve happiness and reduce burnout in oncologistsMark Clemons, Sasha Mazzarello, Gregory Pond, et al.
Pageof 27

Showing results (241-250 of 267) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163Susan L Ellard, Mark Clemons, Karen A Gelmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of responseNan Soon Wong, Robert A Buckman, Mark Clemons, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2009
Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastasesKristin Harris, Edward Chow, Liying Zhang, et al.
Cancer Research|August 14, 2015
Perivascular M2 Macrophages Stimulate Tumor Relapse after ChemotherapyRussell Hughes, Bin-Zhi Qian, Charlotte Rowan, et al.
Journal of Evaluation in Clinical Practice|January 24, 2019
Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trialSusan J Robertson, Mohammed F K Ibrahim, Carol Stober, et al.
JCO Clinical Cancer Informatics|November 27, 2023
Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data SetsSamer El Kababji, Nicholas Mitsakakis, Xi Fang, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2020
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michael Ong, Carol Stober, et al.
Breast Cancer Research and Treatment|August 21, 2025
Patient perceptions around the use of clinico-pathologic and genomic tools in the management of early breast cancerAna-Alicia Beltran-Bless, Deanna Saunders, Lucas Clemons, et al.
Cell Metabolism|September 15, 2015
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast CancerFanny Dupuy, Sébastien Tabariès, Sylvia Andrzejewski, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 4, 2018
A prospective intervention to improve happiness and reduce burnout in oncologistsMark Clemons, Sasha Mazzarello, Gregory Pond, et al.
Pageof 27